The U.S. Food & Drug Administration recently notified health care professionals and patients that it is aware of four recently published observational studies that looked at the use of Lantus (insulin glargine) and possible risk for cancer in patients with diabetes. Three of the four studies suggest an increased risk for cancer associated with the use of Lantus. The studies, published in the online journal Diabetologia in June, include 301,136 patients treated with insulin in Germany, Sweden and Britain. Findings were significant enough to cause concern, and calls for further testing.

Prescription Lantus is manufactured by French drug maker Sanofi-Aventis, and is used for adults with type 2 diabetes or adults and children (six years and older) with type 1 diabetes who require long-acting insulin for the control of high blood sugar. The company also makes Lantus SoloSTAR, which is a disposable prefilled insulin pen. If you need additional information on this subject contact Ted Meadows at 800-898-2034 or Ted.Meadows@beasleyallen.com.

Other Related Articles

• Avandia – The Diabetes Drug – Is Linked To Higher Risk Of Death
• FDA investigates possible Vytorin-cancer link
• FDA Urged To Test Diabetes Drugs’ Heart Risk
• Arthritis drugs raise cancer risk in children
• Women Who Stop Hormone Use See Breast Cancer Risk Drop